To elucidate the clinical and biological features of childhood acute myeloid leukemia (AML) with the t(8;21), we reviewed the records of patients with AML treated at St Jude Children's Research Hospital over a 17-year period (1980 to 1996). Of 298 patients with AML, 40 (13%) had blast cells that contained the t(8;21). This translocation was associated with a high frequency of French-American-British M2 morphology (82%) and the presence of granulocytic sarcoma (23%). Molecular analysis detected the AML1-ETO fusion transcript in all 25 cases with the t(8;21) tested, but failed to identify additional cases with AML1-ETO among the 127 cases with other cytogenetic findings. Compared to patients with other genetic abnormalities, those with the t(8;21) were less likely to have internal tandem duplications of the FLT3 gene (none of 10 vs 16 of 68). The 6-year overall survival estimate was 55% ± 9% and the event-free survival estimate, 33% ± 7%. Of the clinical and biological features examined, only gender was prognostically significant: the 6-year overall survival estimate for males was 68% ± 10%, compared to 33% ± 11 for female patients (P = 0.03). Treatment outcome was not influenced by the chemotherapy regimen used or by the use of autologous hematopoietic stem cell transplantation. These results suggest that t(8;21)-positive AML represents a heterogeneous disease with variable outcome. The reported favorable outcome for t(8;21)-positive AML in other studies may be due to the use of high-dose cytarabine.
Introduction
Among children and adults with acute myeloid leukemia (AML), the translocation t(8;21) is associated with FrenchAmerican-British (FAB) M2 morphology, a distinctive immunophenotype, and frequent extramedullary disease (EMD). [1] [2] [3] [4] In patients with t(8;21)-positive AML, EMD occurs most commonly as discrete extramedullary collections of leukemic cells, referred to as granulocytic sarcoma (GS), chloroma, or myeloblastoma. 5 Patients whose blast cells contain the t(8;21) appear to have a favorable outcome, especially when treated with regimens containing high-dose cytarabine. [6] [7] [8] [9] Although the results of some studies 2, 10 suggest that the presence of GS adversely affects the prognosis of patients with t(8;21)-positive AML, other reports indicate that GS does not influence their outcome. [11] [12] [13] A recent study of 477 children with AML demonstrated that the presence of extramedullary leukemia, including GS, had no prognostic significance. 14 The t(8;21) disrupts the AML1:CBF␤ transcription factor complex and creates an AML1-ETO fusion gene, whose protein product includes the runt homology domain of AML1 fused to ETO. 15, 16 Like the normal AML1 protein, AML1-ETO binds DNA and interacts with CBF␤. However, AML1-ETO dominantly represses normal AML1-mediated transcriptional activation through interactions with the nuclear co-repressor complex. 16, 17 Characterization of AML1-ETO led to the development of reverse transcriptase polymerase chain reaction (RT-PCR) assays for detecting the fusion transcript. 18 Subsequent studies have demonstrated that molecular assays can occasionally detect AML1-ETO even when conventional cytogenetic analysis fails to detect the t(8;21). [19] [20] [21] [22] [23] [24] [25] In the present study, we report the clinical and biological features and the results of cytogenetic and molecular analyses of 40 cases of t(8;21)-positive childhood AML treated at St Jude Children's Research Hospital.
Patients and methods
Between 1980 and 1996, 298 patients with newly diagnosed primary AML were treated on four consecutive clinical protocols (AML-80, AML-83, AML-87 and AML-91) at this institution. [26] [27] [28] [29] Written informed consent was obtained from patients or their legal guardians, and all studies (therapeutic and diagnostic) were approved by the Institutional Review Board. Diagnoses were based on standard techniques and cases were classified morphologically according to the FAB criteria. Cytogenetic analysis was performed as previously described. 30 Survival was defined as the time interval from diagnosis to death from any cause or to last follow-up visit. The median length of follow-up for all patients was 4.30 years (range, 0.005 to 17.79 years), whereas the median follow-up for patients remaining in first complete remission was 11.82 years (range, 5.82 to 17.76 years). For determination of event-free survival (EFS), an event was defined as a relapse, disease progression, or death from any cause. The date of first event was used in the calculation of EFS. Patients whose disease did not enter complete remission were assigned an EFS value of zero. Time was censored at the last follow-up visit if no treatment failure was observed. The estimates of survival were calculated by using the Kaplan-Meier method 31 and the standard errors (s.e.) were obtained using the method of Peto. 32 Comparisons between survival distributions were made by using the exact log-rank test. Differences in the distribution of clinical and biologic features between patients with t(8;21) and patients without t(8;21) were analyzed by the two-tailed Fisher's exact test. Student's t-test was used to compare the average age at diagnosis between patients with and without t(8;21). All statistical analyses used SAS Release 8.1.
Results
Of the 298 patients with AML, 40 (13%) had leukemic blasts that contained the t(8;21)(q22;q22). Molecular studies were performed on leukemic blasts from 152 patients, including 25 with t(8;21)-positive AML. The AML1-ETO fusion transcript was detected in all 25 patients with t(8;21)-positive AML but in none of the remaining 127 patients. Internal tandem duplication (ITD) of FLT3 was not found in 10 of the patients with t(8;21)-positive AML tested. In contrast, the duplication was detected in 16 (24%) of the other 68 patients tested. The t(8;21) was observed in the leukemic blast cells of patients between the ages of 3 and 20 years but not in cells from younger children or infants with AML (Tables 1 and 2 ). The proportion of male patients did not differ significantly between patients with t(8;21)-positive AML (63%) and patients with t(8;21)-negative AML (53%) (P = 0.09), nor was there a significant difference in the proportion of patients with leukocyte counts less than 50 × 10 9 /l (82% vs 68% for patients without the t(8;21); P = 0.09). As expected, FAB M2 AML occurred more frequently among patients with t(8;21)-positive AML (82%) than among patients with t(8;21)-negative AML (18%, P Ͻ 0.001). Nine (23%) of the 40 patients had GS at the time of diagnosis, including five with skull lesions, two with orbital lesions, and two with epidural masses (Table 2) .
For 15 (eight boys and seven girls) of the 40 patients with t(8;21)-positive AML, the t(8;21) was the sole chromosomal abnormality ( Table 2) . The other 25 patients had additional chromosomal abnormalities. The most frequent was a missing sex chromosome (16 of 25, 64%): a Y chromosome was missing in 13 patients and an X chromosome in three. An additional der(21)t(8;21) was observed in blast cells from three patients, one as a sideline. Other numerical abnormalities included +8 (two patients) and −9, +12, +15, or +18 (one patient each). Additional structural abnormalities included del(9q) (three patients) and ins(2;X), add(7p), del(7q), or del(10p) (one patient each). Interestingly, six of 40 patients (15%) had blast cells that contained complex rearrangements involving three chromosomes (Table 2) .
We have previously demonstrated a high frequency of CD19 and CD56 expression in t(8;21)-positive AML. 1 Of patients whose disease has been analyzed since that report, 87% had blasts that expressed CD19, and 50% had blasts that With a median follow-up time of 4.3 years (range, 0 to 17.8 years), the 6-year EFS estimate for patients with t(8;21)-positive AML was 33% ± 7%. This outcome is similar to that of patients with inv(16)-positive AML (6-year EFS estimate, 37% ± 11%) but worse than that of patients with the t(9;11) (6-year EFS, 65% ± 11%, Figure 1a ) treated at St Jude. Among patients with t(8;21)-positive AML, no clinical features were significantly associated with EFS, but there was a trend toward a poorer prognosis for female patients (6-year EFS estimates 40% ± 10% for males vs 20% ± 9% for females, P = 0.09, Figure 2a ). The presence of other FAB subtypes, GS, or central nervous system disease did not significantly affect EFS. Similarly, there was no difference in EFS between patients with t(8;21) as the sole cytogenetic abnormality and those with additional abnormalities. In addition, there was no significant difference in EFS between the 11 patients who underwent autologous hematopoietic stem cell transplantation (HSCT; 6-year EFS estimate, 46% ϯ 15%) and those who received only chemotherapy as the primary therapy (6-year EFS estimate, 28% ± 8%; P = 0.49).
Of the 20 t(8;21)-positive patients who relapsed, eight were salvaged with HSCT, resulting in a 6-year overall survival (OS) estimate of 55% ± 8% (Figure 1b ). Because of a higher salvage rate, the OS of patients with the t(8;21) exceeded that of patients with inv(16) (6-year OS estimate, 36% ± 11%); however, it was still worse than that of patients with the t(9;11) (6-year OS estimate, 74% ± 10%, Figure 1b) . Regarding overall survival, the therapy received, morphology, leukocyte count at the time of diagnosis, karyotype, CNS status, and the presence of GS were not prognostically important (Table 3) . However, gender had a significant impact on survival: the 6-year overall survival estimate for males with t(8;21)-positive AML was 68% ± 10%, compared to only 33% ± 11% for female patients (P = 0.03, Figure 2b and Table 3 ).
Discussion
The results of the present study demonstrate that, over a 17-year period, 13% of patients treated for AML at our institution had leukemic blasts that contained the t(8;21). In each instance, the t(8;21) was detected by standard cytogenetic techniques, and, when tested (25/40 cases), confirmed by RT-PCR to express AML1-ETO. No additional cases were detected by RT-PCR analysis alone, even though other reports suggest that molecular assays can detect additional cases with AML1-ETO among cases with other cytogenetic abnormalities. [19] [20] [21] [22] [23] [24] [25] For example, in a study of 64 patients with AML, Andrieu et al 23 found AML1-ETO in the blasts of nine patients by RT-PCR but detected the t(8;21) in only five patients by standard cytogenetic analysis. However, the incidence of cytogenetically cryptic disease was lower in a study by Rowe et al; 25 the t(8;21) was detected in the blasts of 31 patients by cytogenetic analysis, whereas the AML1-ETO fusion was detected in the blasts of 33 patients by RT-PCR. Finally, a recent study suggests that patients whose leukemic blast cells express AML1-ETO but do not show the t(8;21) may have a poorer prognosis than those whose cells contain the t (8;21) . 22 The lack of cytogenetically cryptic disease in the present study in part reflects our ability to perform cytogenetic analyses on fresh (rather WBC, white blood cell; CNS, central nervous system status: 1, no blasts; 2, Ͻ5 WBC per l with blasts present; 3, Ͼ5 WBC per l with blasts present; GS, granulocytic sarcoma; FAB, French-American-British; EFS, event-free survival; Hem Rel, hematologic relapse; CR, complete remission; EM Rel, extramedullary relapse; haplo-HSCT, haploidentical hematopoietic stem cell transplantation; auto-HSCT, autologous hematopoietic stem cell transplantation; allo-HSCT, allogeneic hematopoietic stem cell transplantation. a Sites of GS include skull (patients 16, 18, 22, 31, 32) , orbits (24, 38) , and spinal cord (6, 14) .
Figure 1
Kaplan-Meier estimates of event-free survival (a) and overall survival (b) according to genetic subgroup. The numbers in parentheses indicate the number of patients in each subgroup and the values on the curves indicate the 6-year EFS estimates ± standard error.
than shipped) bone marrow aspirates obtained at the time of diagnosis.
Recently, mutations and internal tandem duplications (ITD) of the FLT3 gene have been associated with a poor prognosis in both adults and children with AML. [33] [34] [35] [36] [37] [38] In adults, approximately 25% of AML cases carry these mutations. 33, 36 However, the frequency in t(8;21)-positive AML appears to be lower. In the largest series reported, only two of 28 and six of 67 t(8;21)-positive cases carried FLT3/ITD. 33, 36 In childhood AML, FLT3/ITD is less prevalent, but is still associated with a poor prognosis. 34, 37 In a study of 94 cases of childhood AML in Japan, FLT3/ITD was detected in five cases, none of which carried the t(8;21). 34 A study of 91 cases treated on Children's Cancer Group trials demonstrated an 8-year EFS estimate of only 7% for the 15 cases with FLT3/ITD. 37 In that study, only one of the 15 positive cases contained the t(8;21). In the present study, we have confirmed the low frequency of FLT3/ITD in t(8;21)-positive AML: none of the 16 FLT3/ITDpositive cases carried the t(8;21) and none of 10 t(8;21)positive cases tested contained FLT3/ITD. Therefore, the relatively poor outcome in our series is clearly not due to the presence of FLT3/ITD.
The results of many studies of adults and children with AML suggest that the t(8;21) is associated with a relatively favorable prognosis. 39 The Medical Research Council 9 reported a 5-year survival estimate of 69%, whereas the Pediatric Oncology (16) was better than that of all other patients with AML; their outcome was particularly good when they were treated with high-dose cytarabine. 6 The CALGB subsequently showed that patients with t(8;21)-positive AML have an even better outcome when treated with multiple courses of high-dose cytarabine than when treated with only one cycle of this agent. 7 In the present study, the primary cause of treatment failure was relapse. Only three patients died while the disease was in remission, whereas 20 experienced disease relapse and four had disease that did not enter remission. Although GS was a frequent finding, it did not affect outcome. Similarly, cytogenetic or immunophenotypic findings did not have any statistically significant influence on survival. Interestingly, gender proved to be the only significant prognostic factor; the overall survival of males was twice that of females. However, the difference in EFS between males and females did not reach statistical significance. In addition, it must be noted that because of the relatively small number of patients, multivariate analyses could not be performed. Therefore, we cannot make definitive conclusions about the impact of gender on the outcome of children with t(8;21)-positive AML.
The relatively poor outcome of patients with t(8;21)-positive AML in this report is probably related to the absence of highdose cytarabine in the treatment regimens. Patients treated on the AML-80 protocol received low daily doses of cytarabine (200 mg/m 2 ) by continuous infusion during two induction and nine consolidation courses of therapy. 26 Those treated on the AML-83 protocol received a combination of etoposide and cytarabine as the initial induction course, but again cytarabine was administered at low daily doses (200 mg/m 2 ) by continuous infusion during induction therapy and by short infusion during continuation therapy. 27 Patients treated on the AML-87 protocol received individualized doses of etoposide and cytarabine, with an initial cytarabine dose of 500 mg/m 2 and subsequent adjustment to doses sufficient to achieve cytarabine plasma concentrations of 1 M. 28 Finally, patients treated on the AML-91 protocol received 2-chlorodeoxyadenosine as initial therapy followed by induction therapy with cytarabine at daily doses of 250 mg/m 2 by continuous infusion. 29 Patients without matched sibling donors then underwent autologous bone marrow transplantation as postremission therapy. Therefore, although all four treatment protocols included cytarabine and daunomycin, two drugs considered standard treatment for AML, as well as other chemotherapeutic agents, they did not include high-dose cytarabine (1-3 g/m 2 ). It is plausible that the suboptimal outcome reported here is related to this lack of high-dose cytarabine therapy.
In conclusion, we have confirmed the association of the t(8;21) with M2 morphology, frequent extramedullary leukemia, and CD19 expression. We also noted a lack of FLT3 ITD in these cases, but could not demonstrate a favorable outcome for patients with this translocation. These results highlight the impact of treatment regimen on the prognostic significance of genetic features. In addition, these results demonstrate that t(8;21)-positive AML represents a heterogeneous disease with regard to clinical and biologic features, as well as outcome. We hope to use gene expression profiling to identify the cases that may be cured with less intensive therapy and those that are likely to have more resistant disease. We also plan to use genotype-directed, risk-adapted therapy to improve the survival of patients with childhood AML. In this regard, until specific therapies are developed to target the AML1-ETO protein, patients with the t(8;21) or AML1-ETO will be treated with regimens that contain high-dose cytarabine.
